2022 World Conference on Lung Cancer (ePosters)-EP16.04-014. NTRK in Lung Cancer Patients with History of Hodgkin's Lymphoma

Pdf Summary

Patients with history of Hodgkin's lymphoma (HL) are typically long survivors, but a small group of them are at higher risk of relapse. The main causes of death in this subgroup are treatment-related toxicities, cardiovascular comorbidities, and second malignancies. Lung cancer (LC) is a common second tumor observed in patients with a history of HL, with thoracic radiotherapy and individual risk factors playing a significant role in its development.<br /><br />To investigate the molecular factors involved in secondary LC, a retrospective study was conducted on patients diagnosed with HL who subsequently developed LC. The study analyzed their epidemiological, clinical, and tumor characteristics, including molecular factors. Next-generation sequencing (NGS) was performed on tumor biopsies to detect NTRK mutations, as previous studies have indicated their presence in this scenario.<br /><br />The results of the study did not detect any molecular alterations in LC patients with a history of HL. While previous thoracic radiotherapy and individual risk factors were found to be relevant in the development of secondary LC, further research is needed to determine if other molecular alterations may be involved. The aim is to conduct a complete sequencing panel to identify possible molecular alterations in this specific subset of patients, as there is limited research in this area.<br /><br />The study included a total of 12 patients who developed LC out of 403 patients diagnosed with HL. The median age at diagnosis for HL was 42 years, while for LC it was 59 years. The majority of patients were male (75%). The histologic subtypes of Hodgkin's lymphoma included nodular sclerosis, mixed cellularity, and nodular lymphocyte predominant HL. Adenocarcinoma was the most common subtype of lung cancer observed.<br /><br />In terms of treatment, chemotherapy and radiotherapy were commonly used for both HL and LC. However, stem cell transplantation, surgery, and palliative care were also employed depending on individual cases. Molecular analysis of the LC tumor samples did not detect any NTRK mutations, and only one patient had an ALK translocation. Out of the 12 patients, 7 died, with 5 of them due to LC progression and 2 due to cardiovascular comorbidities.<br /><br />Overall, this study highlights the need for further research to understand the molecular factors involved in the development of secondary lung cancer in patients with a history of Hodgkin's lymphoma.

Asset Subtitle

Mariola Blanco Clemente

Meta Tag

Speaker Mariola Blanco Clemente

Topic Tumour Biology and Biomarkers - Tumour Biology & Preclinical Studies

Keywords

Hodgkin's lymphoma

relapse risk

treatment-related toxicities

lung cancer

thoracic radiotherapy

individual risk factors

molecular factors

retrospective study

NTRK mutations

histologic subtypes